Literature DB >> 10664795

Mechanisms of action of phospholipid analogs as anticancer compounds.

T Wieder1, W Reutter, C E Orfanos, C C Geilen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10664795     DOI： 10.1016/s0163-7827(99)00004-1

Source DB:  PubMed          Journal:  Prog Lipid Res        ISSN： 0163-7827            Impact factor:   16.195


× No keyword cloud information.
  10 in total

1.  Oral azithromycin versus its combination with miltefosine for the treatment of experimental Old World cutaneous leishmaniasis.

Authors:  Eglal I Amer; Maha M Eissa; Shereen F Mossallam
Journal:  J Parasit Dis       Date:  2014-08-31

2.  Therapeutic switching in leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs.

Authors:  Nishi Shakya; Preeti Bajpai; Suman Gupta
Journal:  J Parasit Dis       Date:  2011-05-20

3.  Inositoylated platelet-activating factor (Ino-C2-PAF) modulates dynamic lymphocyte-endothelial cell interactions and alleviates psoriasis-like skin inflammation in two complementary mouse models.

Authors:  Susann Forkel; Margarete Schön; Annette Hildmann; Anna Claßen; Swen-Malte John; Kerstin Danker; Michael P Schön
Journal:  J Invest Dermatol       Date:  2014-04-08       Impact factor: 8.551

4.  Alterations in the homeostasis of phospholipids and cholesterol by antitumor alkylphospholipids.

Authors:  José M Jiménez-López; Pablo Ríos-Marco; Carmen Marco; Josefa L Segovia; María P Carrasco
Journal:  Lipids Health Dis       Date:  2010-03-25       Impact factor: 3.876

5.  Possible mechanism of miltefosine-mediated death of Leishmania donovani.

Authors:  Navin K Verma; Chinmoy S Dey
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

6.  Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug.

Authors:  F Javier Pérez-Victoria; Santiago Castanys; Francisco Gamarro
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

7.  Testing the hypothesis that amphiphilic antineoplastic lipid analogues act through reduction of membrane curvature elastic stress.

Authors:  Marcus Dymond; George Attard; Anthony D Postle
Journal:  J R Soc Interface       Date:  2008-11-06       Impact factor: 4.118

8.  Preparation, Pharmacokinetics, and Antitumor Potential of Miltefosine-Loaded Nanostructured Lipid Carriers.

Authors:  Guo Yu; Zakir Ali; Anam Sajjad Khan; Kalim Ullah; Humzah Jamshaid; Alam Zeb; Muhammad Imran; Sadia Sarwar; Han-Gon Choi; Fakhar Ud Din
Journal:  Int J Nanomedicine       Date:  2021-05-11

9.  Treatment of Schistosoma mansoni with miltefosine in vitro enhances serological recognition of defined worm surface antigens.

Authors:  Marwa H El-Faham; Maha M Eissa; Joseph E Igetei; Eglal I Amer; Susan Liddell; Mervat Z El-Azzouni; Michael J Doenhoff
Journal:  PLoS Negl Trop Dis       Date:  2017-08-25

10.  Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management.

Authors:  Shyam Sundar; Piero L Olliaro
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.